Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells

卵巢癌的免疫原性受组织驻留记忆T细胞祖细胞亚群的调控。

阅读:3
作者:Carmen M Anadon,Xiaoqing Yu,Kay Hänggi,Subir Biswas,Ricardo A Chaurio,Alexandra Martin,Kyle K Payne,Gunjan Mandal,Patrick Innamarato,Carly M Harro,Jessica A Mine,Kimberly B Sprenger,Carla Cortina,John J Powers,Tara Lee Costich,Bradford A Perez,Chandler D Gatenbee,Sandhya Prabhakaran,Douglas Marchion,Mirjam H M Heemskerk,Tyler J Curiel,Alexander R Anderson,Robert M Wenham,Paulo C Rodriguez,Jose R Conejo-Garcia

Abstract

Despite repeated associations between T cell infiltration and outcome, human ovarian cancer remains poorly responsive to immunotherapy. We report that the hallmarks of tumor recognition in ovarian cancer-infiltrating T cells are primarily restricted to tissue-resident memory (TRM) cells. Single-cell RNA/TCR/ATAC sequencing of 83,454 CD3+CD8+CD103+CD69+ TRM cells and immunohistochemistry of 122 high-grade serous ovarian cancers shows that only progenitor (TCF1low) tissue-resident T cells (TRMstem cells), but not recirculating TCF1+ T cells, predict ovarian cancer outcome. TRMstem cells arise from transitional recirculating T cells, which depends on antigen affinity/persistence, resulting in oligoclonal, trogocytic, effector lymphocytes that eventually become exhausted. Therefore, ovarian cancer is indeed an immunogenic disease, but that depends on ∼13% of CD8+ tumor-infiltrating T cells (∼3% of CD8+ clonotypes), which are primed against high-affinity antigens and maintain waves of effector TRM-like cells. Our results define the signature of relevant tumor-reactive T cells in human ovarian cancer, which could be applicable to other tumors with unideal mutational burden.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。